Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Notes Payables (2017 - 2025)

Dr Reddys Laboratories (RDY) has 8 years of Notes Payables data on record, last reported at $153.2 million in Q1 2024.

  • For Q1 2024, Notes Payables rose 70.42% year-over-year to $153.2 million; the TTM value through Mar 2024 reached $153.2 million, up 70.42%, while the annual FY2025 figure was $445.0 million, 189.53% up from the prior year.
  • Notes Payables reached $153.2 million in Q1 2024 per RDY's latest filing, up from $89.9 million in the prior quarter.
  • Across five years, Notes Payables topped out at $360.2 million in Q1 2022 and bottomed at $89.9 million in Q1 2023.
  • Average Notes Payables over 5 years is $229.5 million, with a median of $226.9 million recorded in 2020.
  • Peak YoY movement for Notes Payables: tumbled 75.04% in 2023, then soared 70.42% in 2024.
  • A 5-year view of Notes Payables shows it stood at $226.9 million in 2020, then soared by 39.82% to $317.3 million in 2021, then grew by 13.51% to $360.2 million in 2022, then crashed by 75.04% to $89.9 million in 2023, then skyrocketed by 70.42% to $153.2 million in 2024.
  • Per Business Quant database, its latest 3 readings for Notes Payables were $153.2 million in Q1 2024, $89.9 million in Q1 2023, and $360.2 million in Q1 2022.